Registered number: 08322823

OSTARA BIOMEDICAL LIMITED UNAUDITED FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 MARCH 2020

Integral Finance Limited

BioHub at Alderley Park Alderley Park Alderley Edge SK10 4TG

Ostara Biomedical Limited Unaudited Financial Statements For The Year Ended 31 March 2020

Contents

	Page
Balance Sheet	1-2
Notes to the Financial Statements	3-5

Ostara Biomedical Limited Balance Sheet As at 31 March 2020

Registered number: 08322823

	202		2020 20		019	
	Notes	£	£	£	£	
FIXED ASSETS						
Intangible Assets	3		1,083,586		674,642	
Tangible Assets	4		1,793		1,891	
		•				
			1,085,379		676,533	
CURRENT ASSETS						
Debtors	5	117,772		49,354		
Cash at bank and in hand		544,736 ————	-	64,796 		
		662,508		114,150		
Creditors: Amounts Falling Due Within One Year	6	(46,750)	-	(4,983)		
NET CURRENT ASSETS (LIABILITIES)			615,758		109,167	
TOTAL ASSETS LESS CURRENT LIABILITIES			1,701,137		785,700	
NET ASSETS		:	1,701,137		785,700	
CAPITAL AND RESERVES						
Called up share capital	7		1,057		643	
Share premium account			3,141,417		2,171,165	
Profit and Loss Account			(1,441,337)		(1,386,108)	
SHAREHOLDERS' FUNDS		:	1,701,137		785,700	

Ostara Biomedical Limited Balance Sheet (continued) As at 31 March 2020

For the year ending 31 March 2020 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

Directors' responsibilities:

- The members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.
- The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.
- These accounts have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies' regime.
- The company has taken advantage of section 444(1) of the Companies Act 2006 and opted not to deliver to the registrar a copy of the company's Profit and Loss Account.

On behalf of the board
Dr Nadia Orsi

Director

13 January 2021

The notes on pages 3 to 5 form part of these financial statements.

Ostara Biomedical Limited Notes to the Financial Statements For The Year Ended 31 March 2020

1. Accounting Policies

1.1. Basis of Preparation of Financial Statements

The financial statements are prepared under the historical cost convention and in accordance with the FRS 102 Section 1A Small Entities - The Financial Reporting Standard applicable in the UK and Republic of Ireland and the Companies Act 2006.

1.2. Intangible Fixed Assets and Amortisation - Goodwill

Goodwill is the difference between amounts paid on the acquisition of a business and the fair value of the separable net assets.

1.3. Research and Development

Expenditure on research and development is written off in the year it is incurred, except where the directors are satisfied that development expenditure incurred on an individual project is carried forward as permitted by FRS102, when its future recoverability can be regarded as assured. The expenditure carried forward is treated as an intangible fixed asset and amortised as to match the expenditure with the anticipated sales from the related project. Provision is made for an impairment.

1.4. Tangible Fixed Assets and Depreciation

Tangible fixed assets are measured at cost less accumulated depreciation and any accumulated impairment losses. Depreciation is provided at rates calculated to write off the cost of the fixed assets, less their estimated residual value, over their expected useful lives on the following bases:

Computer Equipment

4 years

1.5. Foreign Currencies

Monetary assets and liabilities in foreign currencies are translated into sterling at the rates of exchange ruling at the balance sheet date. Transactions in foreign currencies are translated into sterling at the rate ruling on the date of the transaction. Exchange differences are taken into account in arriving at the operating profit.

2. Average Number of Employees

Average number of employees, including directors, during the year was as follows:

	2020	2019
Office and administration	2	2
	2	2

Intangible Assets

	Goodwill	Development Costs	Total
	£	£	£
Cost			
As at 1 April 2019	2	674,640	674,642
Additions	-	408,944	408,944
As at 31 March 2020	2	1,083,584	1,083,586
Net Book Value			
As at 31 March 2020	2	1,083,584	1,083,586
As at 1 April 2019	2	674,640	674,642

Ostara Biomedical Limited Notes to the Financial Statements (continued) For The Year Ended 31 March 2020

4. Tangible Assets		
		Computer Equipment
		£
Cost		
As at 1 April 2019		3,489
Additions		310
As at 31 March 2020		3,799
Depreciation		
As at 1 April 2019		1,598
Provided during the period		408
As at 31 March 2020		2,006
Net Book Value		
As at 31 March 2020		1,793
As at 1 April 2019		1,891
5. Debtors		
	2020	2019
	£	£
Due within one year		
Prepayments and accrued income	89,977	10,591
Corporation tax recoverable assets	-	288
VAT	<u>27,795</u>	38,475
	117,772	49,354
6. Creditors: Amounts Falling Due Within One Year		
o. Cicultors, Amounts running Duc Within One Tear	2020	2019
	£	£
Trade creditors	44,686	- 2,920
Other taxes and social security		2,920
Other creditors	505	80
Accruals and deferred income	1,559	1,713
	46,750	4,983

Ostara Biomedical Limited Notes to the Financial Statements (continued) For The Year Ended 31 March 2020

7. Share Capital

			2020	2019
Allotted, Called up and fully paid		=	1,057	643
	Value	Number	2020	2019
Allotted, called up and fully paid	£		£	£
Ordinary Shares	0.010	105678	1,057	643

	Nominal value	Number	Amount
Shares issued during the period:	£		£
Ordinary Shares	0.010	41378	414

8. General Information

Ostara Biomedical Limited is a private company, limited by shares, incorporated in England & Wales, registered number 08322823. The registered office is 131 Mount Pleasant, Liverpool, Merseyside, L3 5TF.

lectronic form, authenticat	ion and maimer or d	envery under section	n 1072 or the Compa	illes Act 2006.	